Kissei Pharmaceutical Co., Ltd. (TYO: 4547)

Kissei Pharmaceutical Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Cash & Equivalents	26,444	22,894	25,893	30,013	20,456	36,329
Short-Term Investments	23,517	23,039	23,706	23,139	23,998	23,342
Cash & Short-Term Investments	49,961	45,933	49,599	53,152	44,454	59,671
Cash Growth	5.10%	-7.39%	-6.68%	19.57%	-25.50%	20.88%
Receivables	27,433	27,790	22,083	21,956	23,058	19,462
Inventory	26,311	26,296	22,798	18,987	20,118	13,438
Other Current Assets	3,304	4,532	6,161	5,247	5,335	4,106
Total Current Assets	107,009	104,551	100,641	99,342	92,965	96,677
Property, Plant & Equipment	26,149	24,861	24,579	24,074	24,290	24,605
Long-Term Investments	124,857	128,910	94,034	112,574	149,365	108,286
Goodwill	-	309	-	-	-	-
Other Intangible Assets	1,863	1,683	1,507	1,569	1,640	1,511
Long-Term Deferred Tax Assets	459	608	433	524	585	677
Other Long-Term Assets	2	2	1	1	2	2
Total Assets	260,339	260,929	221,200	238,087	268,861	231,794
Accounts Payable	5,243	4,893	4,617	4,104	7,909	5,237
Accrued Expenses	1,774	1,856	1,679	1,721	1,830	1,866
Short-Term Debt	1,260	1,340	1,490	1,640	1,743	1,746
Current Income Taxes Payable	2,145	2,380	408	3,497	1,487	196
Other Current Liabilities	9,026	7,194	6,763	7,782	5,276	7,979
Total Current Liabilities	19,448	17,663	14,957	18,744	18,245	17,024
Long-Term Debt	-	-	-	-	-	13
Long-Term Deferred Tax Liabilities	19,257	21,188	10,426	16,259	28,480	17,191
Other Long-Term Liabilities	671	735	812	724	786	851
Total Liabilities	39,569	39,795	26,387	35,908	48,909	38,826
Common Stock	24,356	24,356	24,356	24,356	24,356	24,356
Additional Paid-In Capital	24,226	24,226	24,226	24,226	24,226	24,226
Retained Earnings	130,747	127,310	125,576	118,183	109,270	106,461
Treasury Stock	-13,209	-13,209	-12,912	-12,912	-12,911	-11,608
Comprehensive Income & Other	53,537	57,344	32,653	47,532	74,373	49,029
Total Common Equity	219,657	220,027	193,899	201,385	219,314	192,464
Minority Interest	1,113	1,107	914	794	638	504
Shareholders' Equity	220,770	221,134	194,813	202,179	219,952	192,968
Total Liabilities & Equity	260,339	260,929	221,200	238,087	268,861	231,794
Total Debt	1,260	1,340	1,490	1,640	1,743	1,759
Net Cash (Debt)	48,701	44,593	48,109	51,512	42,711	57,912
Net Cash Growth	5.54%	-7.31%	-6.61%	20.61%	-26.25%	26.81%
Net Cash Per Share	1096.87	985.30	1043.24	1117.03	915.25	1239.66
Filing Date Shares Outstanding	44.21	44.21	45.96	46.12	46.12	46.72
Total Common Shares Outstanding	44.21	44.21	46.12	46.12	46.12	46.72
Working Capital	87,561	86,888	85,684	80,598	74,720	79,653
Book Value Per Share	4969.03	4977.38	4204.63	4366.94	4755.71	4119.86
Tangible Book Value	217,794	218,035	192,392	199,816	217,674	190,953
Tangible Book Value Per Share	4926.89	4932.32	4171.95	4332.92	4720.15	4087.51
Order Backlog	-	2,613	2,098	1,479	2,726	3,351

Source: S&P Capital IQ. Standard template. Financial Sources.